- |||||||||| Leukeran (chlorambucil) / GSK
Journal: Multicharge β-cyclodextrin supramolecular assembly for ATP capture and drug release. (Pubmed Central) - Jul 14, 2021
A hyaluronidase-responsive polysaccharide supramolecular assembly was constructed from an amphiphilic β-cyclodextrin bearing seven hexylimidazolium units (AMCD), adamantyl-grafted hyaluronic acid, and chlorambucil, which showed specific cancer cell targeting and controlled drug release abilities. Interestingly, ternary supramolecular assembly can disassemble in the presence of hyaluronidase, and the released AMCD can assemble with ATP to form a stable 1 : 1 complex, which enhanced the efficacy of chlorambucil on cancer chemotherapy by inhibiting ATP hydrolysis.
- |||||||||| ifosfamide / Generic mfg., methotrexate / Generic mfg.
Clinical, Review, Journal: Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review. (Pubmed Central) - Jul 10, 2021
We carried out an exhaustive review of the literature and adopted 48 manuscripts consisting of 66 HD patients undergoing 71 chemotherapy regimens for NHL, summarized the data, and provide recommendations concerning dose adjustments and timing of administration for individual chemotherapeutics where possible. Chemotherapy regimens studied in this review include, but are not limited to, rituximab, CVP and CHOP-like regimens, chlorambucil, ibrutinib, bendamustine, methotrexate, platinum compounds, cytarabine, gemcitabine, etoposide, ifosfamide, melphalan, busulfan, fludarabine, mogamulizumab, brentuximab vedotin, and Y-ibritumomab tiuxetan.
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen
Trial completion: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (clinicaltrials.gov) - Jul 9, 2021
P=N/A, N=50, Completed,
Chemotherapy regimens studied in this review include, but are not limited to, rituximab, CVP and CHOP-like regimens, chlorambucil, ibrutinib, bendamustine, methotrexate, platinum compounds, cytarabine, gemcitabine, etoposide, ifosfamide, melphalan, busulfan, fludarabine, mogamulizumab, brentuximab vedotin, and Y-ibritumomab tiuxetan. Active, not recruiting --> Completed
- |||||||||| Revlimid (lenalidomide) / BMS, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] CONSTRUCTION OF AN INFORMATION GUIDE FOR THE MANAGEMENT OF ANTINEOPLASTIC AND SUPPORT DRUGS VIA PROBE. () - Jul 2, 2021 - Abstract #ICUC2021ICUC_306;
The information provided by the information guide is intended to support oncology professionals in prescribing and correctly administering oral solids via enteral tube. In the literature review, important points such as the use of an oral meter, a device that ensures accuracy and reduces waste, and the correct location of the probe were emphasized in this guide.
- |||||||||| Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Biomarker, Retrospective data, Journal: Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study. (Pubmed Central) - Jun 26, 2021
Cytogenetic abnormalities including complex karyotypes (≥ 3), del(11q), and del(17) had a significantly adverse impact on both OS and PFS (p < 0.001 and p = 0.010, respectively). Initial hyperleukocytosis, extranodal involvement, complex karyotype, del(17) and del(11q) need to be considered in the risk stratification system for CLL.
- |||||||||| methotrexate / Generic mfg.
Journal: A host-guest drug delivery nanosystem for supramolecular chemotherapy. (Pubmed Central) - Jun 22, 2021
The supramolecular nanodrugs achieved higher anticancer performances compared with free drugs in cell experiments. Furthermore, the cellular uptake mechanisms and efficacy are confirmed by fluorescence imaging.
- |||||||||| Calquence (acalabrutinib) / AstraZeneca
Clinical, European regulatory, Review, Journal: The European Medicines Agency Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia. (Pubmed Central) - Jun 22, 2021
The first trial (ACE-CL-007) randomly allocated acalabrutinib versus AcalaObi versus chlorambucil plus obinutuzumab (ChlObi) to elderly/unfit patients with TN CLL...The second trial (ACE-CL-309) randomly allocated acalabrutinib versus rituximab plus idelalisib or bendamustine to adult patients with RR CLL...Acalabrutinib resulted in a clinically meaningful and significant lengthening of the time from treatment initiation to further disease relapse or patient's death compared to standard therapy. The overall safety profile was considered acceptable, and the benefit-risk ratio was determined to be positive.
- |||||||||| Leukeran (chlorambucil) / GSK
Journal: Conjugate of podophyllotoxin with chlorambucil: synthesis, biological testing and molecular modeling (Pubmed Central) - Jun 22, 2021
The conjugate inhibited proliferation (IC50=135±30 nM) and growth (EC50=240±30 nM) of A549 cells. The data of computer molecular docking of the novel compound into the 3D model of the colchicine binding site in α,β-tubulin and molecular dynamics modelling allowed to explain the observed difference in effects of chlorambucil-podophyllotoxin and chlorambucil-colchicine conjugates on microtubules.
- |||||||||| imatinib / Generic mfg.
[VIRTUAL] TARGETED THERAPIES IN CHRONIC LEUKEMIAS () - Jun 20, 2021 - Abstract #ICLLM2021ICLLM_117;
Targeted antineoplastic therapy proved to be efficient in the newly diagnosed and relapsed cases regardless of the type of chronic leukemias and patient’s age. CLL relapse after rituximab-containing regimens may be considered as the indication for the kinase-targeting therapy with ibrutinib.
- |||||||||| Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] DIAGNOSIS AND TREATMENT OPTIONS IN LOW-RISK AND PROGRESSIVE CHRONIC LYMPHOCYTIC LEUKEMIA () - Jun 20, 2021 - Abstract #ICLLM2021ICLLM_112;
Singleagent chemotherapy with chlorambucil and rituximab were indicated in cases with stage B. Combination chemotherapy (COP, CHOP, R-COP) and radiotherapy were administered in patients, who progressed into stage C. CLL developed in 67 (81.7%) patients during the first 6 months from the onset. CLL commonly affected males, and was diagnosed in stage A. The overall survival correlated with CLL stage, and turned out to be lower in stage B and higher in the cases treated with combined regimens.
- |||||||||| Leukeran (chlorambucil) / GSK
Clinical, Journal: Early clinical trials in chronic lymphocytic leukaemia in the UK. (Pubmed Central) - Jun 16, 2021
This is an historical account of the randomised trials in chronic lymphocytic leukaemia in the UK between the years 1978 to 2004, describing their gestation, the treatments used and the main lessons learnt. Those lessons include: (1) how best to use chlorambucil, which was the first effective treatment for CLL; (2) the significant difference in survival between the sexes; and (3) the value of prognostic markers, both morphological and molecular, which continue to be relevant to current practice.
- |||||||||| Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] MANTLE CELL LYMPHOMA, A SINGLE CENTER EXPERIENCE () - Jun 11, 2021 - Abstract #ICML2021ICML_591;
A significant improvement of its outcome has been achieved by the administration of Rituximab (R) based regimens and the intensification of first line treatment by high dose Cytarabine and autologous stem cell transplantation...Nineteen patients received R - Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (R-CHOP), 11 an intensified regimen, 14 patients R -Bendamustin, 5 patients R - Chlorambucil and 2 subjects had no treatment...The treatments administered were: R-CHOP (6 patients), R-Bendamustin (6 patients), platinum based regimens (3 patients), Ibrutinib (5 patients), corticosteroids (2 patients), R - Chlorambucil (1 patient)... Increasing the percentage of 1st complete response by intensifying the 1st line treatment could improve the survival of patients with MCL.
- |||||||||| Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] CLINICAL CHARACTERISTICS AND OUTCOMES OF WALDENSTRÖM MACROGLOBULINEMIA PATIENTS, TREATED AND FOLLOWED IN A PUBLIC BRAZILIAN CENTER. () - Jun 11, 2021 - Abstract #ICML2021ICML_586;
The most prescribed protocols were CVP (n = 10), CHOP (n = 5), Fludarabine (n = 4), chlorambucil (n = 4) and FC (n = 3)...Moreover, genotype test is not reimbursed and there is no approval for Rituximab, Bendamustine or Bruton tyrosine kinase inhibitors in Brazil's public health system for WM...Efforts should be made to perform genotype tests and make available specific treatment for MW. Medical education, establishment of a reference center and a national registry may improve knowledge of MW and outcomes of patients in Brazil and other countries.
- |||||||||| Leukeran (chlorambucil) / GSK
Journal: Targeting of GLUT5 for Transporter-Mediated Drug-Delivery Is Contingent upon Substrate Hydrophilicity. (Pubmed Central) - Jun 10, 2021
The proof-of-concept analysis was carried out for conjugates of chlorambucil (CLB) in GLUT5-positive breast cancer cells and normal breast cells...The differences were found to relate to the loss of GLUT5-mediated uptake upon increased conjugate size and hydrophobicity. The findings provide information on the substrate tolerance of GLUT5 and highlight the importance of maintaining appropriate hydrophilicity for GLUT-mediated delivery.
- |||||||||| Leukeran (chlorambucil) / GSK
Journal: Improvement of the Anticancer Activity of Chlorambucil and Ibuprofen via Calix[4]arene Conjugates. (Pubmed Central) - Jun 3, 2021
Cytotoxicity assays revealed that at 10 μM, the conjugates were very active against K-562 (human chronic myelogenous leukemia cells) and U- 251 (human glioblastoma cells) cancer cells' proliferation. In order to explain the molecular mechanisms involved in the anticancer activity of calix[4]arene chlorambucil or ibuprofen conjugates, our research will be continued.
- |||||||||| ibuprofen / Generic mfg.
Journal: Synthesis and anticancer activity of open-resorcinarene conjugates. (Pubmed Central) - Jun 2, 2021
It was found that the conjugate with chlorambucil, naproxen or indomethacin (having 8 moieties) was toxic towards cancer cell lines U-251 and K-562, with no activity against non-cancerous COS-7 cells. The conjugates with naproxen and indomethacin showed high selectivity towards U-251 tumor cells.
- |||||||||| Calquence (acalabrutinib) / AstraZeneca
Review, Journal: Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies. (Pubmed Central) - Jun 1, 2021
Recent phase 3 data showed that acalabrutinib improved progression-free survival (PFS) compared with rituximab plus idelalisib or rituximab plus bendamustine in patients with relapsed/refractory CLL, and acalabrutinib with or without obinutuzumab improved PFS compared with chlorambucil plus obinutuzumab in patients with treatment-naïve CLL. Overall, acalabrutinib had a tolerable safety profile, with most adverse events being grade 1/2 severity (most commonly headache and diarrhea) and a low rate of discontinuation due to adverse events.
- |||||||||| Leukeran (chlorambucil) / GSK
Clinical, Journal: Follicular lymphoma transforming to DLBCL and reverting back to follicular lymphoma at relapse-a case report. (Pubmed Central) - May 25, 2021
After HT, she was treated with CHOP chemotherapy and the patient relapsed again after 3 years with follicular lymphoma histology. This case highlights the unique and varied natural history of follicular lymphoma that may be attributed to different subclones of malignant cells that may have arisen from a common progenitor FL cell and differential effect of chemotherapy on these subclones.
- |||||||||| Leukeran (chlorambucil) / GSK
Journal: Floxuridine-chlorambucil conjugate nanodrugs for ovarian cancer combination chemotherapy. (Pubmed Central) - May 22, 2021
The cytotoxicity test results show that Fud-Cb nanodrugs can efficiently inhibit the growth of ovarian cancer cells. The apoptosis data exhibit that the cell necrotic and apoptotic rate treated with Fud-Cb nanodrugs is about 73.7 % and 18.76 % within 24 h. These results suggest that Fud-Cb nanodrugs based on ADDC strategy can effectively enhance synergistic anticancer efficacy to ovarian cancer.
- |||||||||| irinotecan / Generic mfg.
Journal: Nuclear delivery of dual anti-cancer drugs by molecular self-assembly. (Pubmed Central) - May 15, 2021
Our nanomedicine exhibited enhanced cellular uptake and nuclear accumulation properties, thus achieving an excellent anti-cancer capacity both in vitro and in vivo. Our study will provide an inspiration for the development of novel multifunctional nanomaterials for cancer diagnosis and therapy.
- |||||||||| Zarzio (filgrastim biosimilar) / Novartis
[VIRTUAL] MYD88 MUTATION IN WALDENSTROMSÖM MACROGLOBULINEMIA AND TREATMENT OUTCOME. A SINGLE CENTRE EXPERIENCE () - May 13, 2021 - Abstract #EHA2021EHA_1469;
Six patients (20%) had relapsed and received a second line therapy (1 FCR, 1 Chlorambucil, 1 Ibrutinib, 1 no further therapy due to extreme age, 1 patient with bi-clonal disease with CLL treated with Idelalisib and Rituximab and 1 moved to another institution)...The overall survival in this study was 65% at 36 months and evaluating the MYD88 mutational status impact was limited due the small sample size and retrospective nature of this study. CXCR4 mutation screening for this study cohort is in progress and longer follow up will continue prospectively.
- |||||||||| Zarzio (filgrastim biosimilar) / Novartis
[VIRTUAL] CHRONIC MYELOID LEUKEMIA AS A SECONDARY MALIGNANCY IN A PATIENT WITH SPLENIC MARGINAL ZONE LYMPHOMA: A CASE REPORT () - May 13, 2021 - Abstract #EHA2021EHA_1337;
From Jun 2012, chlorambucil was applied intermittently, due to thrombocytopenia and progressive enlargement of the spleen...Imatinib treatment was switched to nilotinib (300mg, twice per day) after seven months due to recurrent skin rash and refractory mucous membrane ulcer, which were probably attributed to imatinib...Tr-CML is an infrequent complication after chemotherapy and/or radiotherapy, which may increase the risk of secondary malignancies by inducing genetic damage. Nilotinib, the second generation TKI, could show a favorable response in Ph+ tr-CML, similar to that in de novo CML.
- |||||||||| Zarzio (filgrastim biosimilar) / Novartis
[VIRTUAL] LEUKEMIA CUTIS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE STUDY OF THE FRENCH INNOVATIVE LEUKEMIA ORGANIZATION (FILO) () - May 13, 2021 - Abstract #EHA2021EHA_1267;
Thirty-one patients were treated: 13 patients received a fludarabine or bendamustine-based regimen, 5 chlorambucil based, 5 Ibrutinib, 4 polychemotherapy, 1 obinutuzumab, 2 venetoclax and 1 idelalisib...t(14;18) is enriched and we are currently investigating its significance in this atypical clinical presentation of CLL. Our results suggest that CLL patients with cutaneous lesions are not associated with poor prognosis features and they respond well to CLL systemic treatment.
|
